Member Info for Noise

Apologies I may have got the dates confused on my last post, it seems to be a general aspiration from last year

Yes....amusingly they have also told the Czech press that they want some kind of partnership with the German side of the border, presumably BCN.

I see the inclusion of BCN as a political tactic, why end up in a price war with your neighbours when you get can comfy and control more of the market.

No firm bid price set for EMH....would assume that will follow?

MCAP ~ £30m, potential asset size... £500m on phase 1?

Get up to £1 and I'll think about it.

So, ball back in Krupa's court, how much are they going to offer?

That's true, I can think of worse ways to end my manly days, with less pain I can go about shaving my breasts.

The historic problems with risperidone appear to be that in ~1% of cases a side effect is enlarged breast tissue in men, J&J tried to sell it 'off label' and marketed risperidone for children without apparently the regulatory/safety paperwork to back that up. Frankly with terminal lung cancer growing breasts will be a trivial issue in the grand scheme of things.

I'm on holiday, I'm amused how much conversation took place on a Sunday

Send me some 201 results pleeeeease Satu, love ya x

Minor comment, but if I recall correctly Val could receive 50% of any profit, not 50% gross revenue.

I have absolutely no clue about Bangladeshi healthcare

http://www.thewhpca.org/latest-news/item/new-uk-aid-direct-funded-project-to-build-compassionate-communities-providing-care-for-the-seriously-ill-in-bangladesh-towards-universal-health-coverage

PS best of luck to SCLP and investors, the pipeline is interesting and it seems a pivotal timeline at the moment. Good luck in the GC

Hi Drac, yes, it seems that palliative care hospices are being rolled out in Bangladesh in connection with the UK aid agency, but I have no way to see how that connects to valirx. We'll see. Val101 is theoretically as exciting as 201, but a few years away

Have Mystic done anything yet? If so it seems a bit quiet and hard to research (well, in English media anyway). It's been about 1.5years so maybe they have moved forward somewhat. Did they ever trial patients?

No idea who ADL are.

UKOG is an interesting one. In theory they have plenty of oil, although I don't know whether the logistics of extracting oil from directly below an airport is plausible or recommended. There's been the odd earthquake up North with the fracking

Thanks Ray, I am not clear whether 401 operates like a checkpoint inhibitor, I believe that's more closely related to specific immune system killing of tumour cells.

My (clumsy) analogy is that 401 is akin to applying the handbrake on a moving car when the footbrake has failed.

I had a vague look at Scancell's SC1B2, from recollection it's currently targeting lung cancer, but I am unclear whether it targets other sub-types of cancer (squamous cell carcinoma?).

Scancell seem ok, I haven't invested as I don't have the time to read through their science in detail. I have pondered the reasons why Scancell "investors" seem to bother this board so much, in some manners we should probably take it as a compliment, as they wouldn't be here unless they had a good competitive reason, presumably related to equity raising, grant/partner chasing, or maybe the PR team just get a bit overexcitable when fed too much sugar.

But does she endorse that Adam? ;)

Oh who knows, perhaps there is some underlying connection to the NHS' plans, VAL401 is perfect (due to the reformulation), while VAL201 could be fab in cancer and endo.

lol, it is certainly a strange RNS, nothing specific, just pointing out we are in the right field.

Another research paper showing the link between HSD10 and cancer. VAL401 essentially being used as a HSD10 downregulator to reduce tumour growth.

https://core.ac.uk/download/pdf/81716759.pdf

"Conclusions: Our findings demonstrate that overexpression of HSD10 accelerates pheochromocytoma cell
growth, enhances cell respiration, and increases cellular resistance to cell death induction. This suggests that
blockade of HSD10 may halt and/or prevent cancer growth, thus providing a promising novel target for cancer
patients as a screening or therapeutic option."

While VAL401 trial data was limited to 8 patients, I found some of the anecdotal evidence quite interesting.

The mechanism it works should prevent cancer growth, presumably with a massive reduction in tumour related pain. I found the snippet that a 'significant number' of bedbound terminal patients managed to get out of bed and walk quite an unusual and pleasant quote.

Fingers crossed a deal will come through, Valirx timing would suggest if it's suggested in Q1 then we'll get it by April??

Would love to see a US/EU multiple trial run on various adenocarcinomas, but I assume they'll start with lung cancer. I think I recall that pancreatic, breast and prostate are additional trial options (well, those with a diagnosis of adenocarcinoma anyway).

Oh yes, I totally forgot that New York is getting its first major electric ferry in the next couple of months, covering the Brooklyn to Manhattan commute/journey.

It's quite an integrated offering this one, 150 person e-ferry linking up at each end to e-bikes, e-scooters, e-shuttle taxis etc. Apparently the timing is interesting, because the subway is coincidingly about to close for a few months for repair work.

I think London has two now, running on the Woolwich line.

Antelope, I'm not 100% sure, but if I take the government announcements as gospel ( https://electrek.co/2018/05/04/elecitrc-ferries-norway-fjords-worlds-first-zero-emission-zone/ ) then internal combustion boats will be completely banned from 2026, while the main ferry operators have already ordered several fleets of electric ferries entering service in 2020 (I understand they have several working prototypes, quite large boats too).

Apparently this covers all ~1200 Fjords, the only exceptions being exceptional emergency services and military applications.

It says Alzheimer's disease can be caused by hsd10 overexpression, val401 reduces hsd10, although it's not being tested for that. "The brains of individuals with Alzheimer’s disease (AD) and of animals in an AD mouse model exhibit abnormally elevated levels of 17ß-HSD10. Abnormal expression, as well as mutations of the HSD17B10 gene leads to impairment of the structure, function, and dynamics of mitochondria. This may underlie the pathogenesis of the synaptic and neuronal deficiency exhibited in 17ß-HSD10 related diseases, including 17ß-HSD10 deficiency and AD."